Finch Therapeutics Group, Inc. and its affiliated debtors have filed a First Amended Combined Disclosure Statement and Joint Chapter 11 Plan as part of their ongoing bankruptcy proceedings. The filing was submitted on July 24, 2026, in the U.S. Bankruptcy Court for the District of Delaware. The court granted conditional approval of the combined document solely for the purpose of soliciting votes from creditors.

A hearing to consider final approval of the Chapter 11 plan is scheduled for September 1, 2026. Creditors and other interested parties wishing to object to the plan must submit and serve their objections by August 25, 2026. Additionally, ballots to accept or reject the proposed plan must be completed and returned by August 24, 2026.

The filing includes detailed instructions regarding the voting process, deadlines, and procedures for submitting objections. Information and necessary documents have been made accessible through a designated claims agent’s website, with contact options available via phone and email.

The notice lists the involved Finch Therapeutics entities along with their corresponding tax identification information and specifies the service address. This announcement follows the procedural requirements of Chapter 11 bankruptcy cases and aims to inform creditors of the next steps in the restructuring process.